Introduction: Spasticity is a common symptom among patients with multiple sclerosis (MS).This study aims to assess the effectiveness and safety of the combination of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in clinical practice for the treatment of spasticity in MS. Methods: Retrospective observational study with patients treated with inhaled THC/CBD between April 2008 and March 2012. Descriptive patient and treatment variables were collected. Therapeutic response was evaluated based on the doctor's analysis and overall impression. Results: Of the 56 patients who started treatment with THC/CBD, 6 were excluded because of missing data. We evaluated 50 patients (42% male) with a median age of 47.8 years (25.6–76.8); 38% were d...
IMPORTANCE: Cannabinoids have antispastic and analgesic effects; however, their role in the treatmen...
OBJECTIVE: To test the effectiveness and long term safety of cannabinoids in multiple sclerosis (MS)...
Resumen: Introducción: La espasticidad es un síntoma muy frecuente entre los pacientes con escleros...
Introduction: The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sati...
Background: Tetrahydrocannabinol:cannabidiol (THC:CBD) oromucosal spray (Sativex®) is an add-on ther...
Background/purpose: Spasticity is one of the most common symptoms in people with multiple sclerosis ...
Background Multiple sclerosis is associated with muscle stiffness, spasms, pain, and tremor. Much...
Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray was approved as add-on therapy...
BACKGROUND: The approval of 9-δ-tetrahydocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sati...
Spasticity, one of the main symptoms of multiple sclerosis (MS), can affect more than 80% of MS pati...
A large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impa...
Background: Spasticity and chronic neuropathic pain are common and serious symptoms in people with m...
IMPORTANCE: Cannabinoids have antispastic and analgesic effects; however, their role in the treatmen...
OBJECTIVE: To test the effectiveness and long term safety of cannabinoids in multiple sclerosis (MS)...
Resumen: Introducción: La espasticidad es un síntoma muy frecuente entre los pacientes con escleros...
Introduction: The approval of 9-δ-tetrahydocannabinol (THC)+cannabidiol (CBD) oromucosal spray (Sati...
Background: Tetrahydrocannabinol:cannabidiol (THC:CBD) oromucosal spray (Sativex®) is an add-on ther...
Background/purpose: Spasticity is one of the most common symptoms in people with multiple sclerosis ...
Background Multiple sclerosis is associated with muscle stiffness, spasms, pain, and tremor. Much...
Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) oromucosal spray was approved as add-on therapy...
BACKGROUND: The approval of 9-δ-tetrahydocannabinol and cannabidiol (THC:CBD) oromucosal spray (Sati...
Spasticity, one of the main symptoms of multiple sclerosis (MS), can affect more than 80% of MS pati...
A large proportion of patients with multiple sclerosis (MS) have spasticity, which has a marked impa...
Background: Spasticity and chronic neuropathic pain are common and serious symptoms in people with m...
IMPORTANCE: Cannabinoids have antispastic and analgesic effects; however, their role in the treatmen...
OBJECTIVE: To test the effectiveness and long term safety of cannabinoids in multiple sclerosis (MS)...
Resumen: Introducción: La espasticidad es un síntoma muy frecuente entre los pacientes con escleros...